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How this paper will improve care:  The study adds data about the reliability of commonly-
obtained tumor markers in the setting of an ovarian mass. These findings will help guide the 
preoperative evaluation and risk stratification of patients with concern for ovarian neoplasms. 
Abstract 
Purpose: The purpose of this study was to determine the diagnostic accuracy of tumor markers 
for malignancy in girls with ovarian neoplasms.  
Methods: A retrospective review of girls 2-21 years who presented for surgical management of 
an ovarian neoplasm across 10 children’s hospitals between 2010-2016 was performed. Patients 
who had at least one concerning feature on imaging and had tumor marker testing were included 
in the study. Sensitivity, specificity, and negative and positive predictive values (PPV) of tumor 
markers were calculated.  
Results: Our cohort included 401 patients; 22.4% had a malignancy. Testing for tumor markers 
was inconsistent. AFP had high specificity (98%) and low sensitivity (42%) with a PPV of 86%. The 
sensitivity, specificity, and PPV of beta-hCG was 44%, 76%, and 32%, respectively. LDH had high 
sensitivity (95%) and Inhibin A and Inhibin B had high specificity (97% and 92%, respectively). 
Conclusions: Tumor marker testing is helpful in preoperative risk stratification of ovarian 
neoplasms for malignancy. Given the variety of potential tumor types, no single marker provides 
enough reliability, and therefore a panel of tumor marker testing is recommended if there is 
concern for malignancy. Prospective studies may help further elucidate the predictive value of 
tumor markers in a pediatric ovarian neoplasm population. 
Keywords: Ovarian neoplasms; Tumor markers; Preoperative risk; Oophorectomy; Ovary-
sparing surgery 
Type of Study: Retrospective Cohort Review 













Ovarian masses in children are relatively rare. Ovarian masses can be classified as 
physiologic cysts or neoplasms. Previous studies have shown ovarian neoplasms to occur at an 
annual incidence of 2.2-2.6 cases per 100,000 pediatric patients (1). The rate of malignancy 
among these masses is reported at frequencies ranging from 4% to 27% (1-4). When patients 
present with an ovarian mass without signs or symptoms concerning for torsion or need for 
emergency surgery, adequate time exists for preoperative workup and planning. Recently, efforts 
are being made to promote ovary-sparing surgery in the appropriate setting (5-7). However, one 
of the challenges facing surgeons is how best to preoperatively risk stratify the patient who 
presents with an ovarian neoplasm (3, 4, 8-10). Elements of the patient’s history, physical exam, 
imaging, and laboratory testing may be used to determine the best operative approach for 
patients with ovarian masses that are concerning for malignancy. The goal of this study was to 




A retrospective cohort study was conducted at ten participating institutions of the 
Midwest Pediatric Surgery Consortium (www.mwpsc.org).This study was approved by the 
institutional review boards of each institution with a waiver of consent. All patients receiving 
care at the ten participating institutions meeting eligibility criteria were included in the study. 
Patients were identified using the International Classification of Disease, 9th Edition, Clinical 












ovarian neoplasms. Data were recorded and managed using the Research Electronic Data 
Capture tool. 
Eligibility criteria included female gender, surgical management for ovarian neoplasms 
between January 1, 2010 and December 31, 2016, and age 2-21 years at the time of surgery. 
Electronic medical records were reviewed for patient characteristics, admission characteristics, 
laboratory and imaging results, operative findings, pathology reports, and post-operative 
complications. Patients who had at least one concerning feature for malignancy on imaging (size 
> 8 cm, presence of free fluid, solid components, papillary projections, ill-defined borders, 
extension into surrounding structures, lymphadenopathy, or metastatic or complex components) 
and had tumor marker testing were included in the study (Table 1).  Patients with simple cysts, 
congenital ovarian abnormalities, torsion without a neoplasm, or unavailable pathology results 
were excluded.  
The primary objective of this study was to better understand diagnostic accuracy of tumor 
markers for pediatric ovarian neoplasms. Preoperative tumor markers assessed included beta 
human chorionic gonadotropin (beta-hCG), lactate dehydrogenase (LDH), alpha fetoprotein 
(AFP), cancer antigen 125 (CA-125), cancer antigen 19-9 (CA 19-9), carcinoembryonic antigen 
(CEA), Inhibin A, and Inhibin B. Thresholds for elevated tumor markers were identified a priori 
based on standardized laboratory values at our institutions (Table 2).   
Demographic and clinical characteristics of patients in our at-risk cohort were described 
with frequencies and percentages for categorical variables and medians and interquartile ranges 
for continuous variables. Bivariate relationships between patient characteristics and malignancy 
were assessed using Chi-squared, Fisher’s exact, and Wilcoxon-Mann-Whitney U tests where 














calculated to better understand the association between tumor markers and malignant disease; 
point estimates with exact confidence intervals are reported. All statistical analyses were 
performed using SAS Enterprise Guide Version 7.1 (SAS Institute, Cary, NC).  
Results 
Eight hundred and nineteen patients who underwent surgery for an ovarian neoplasm 
across ten children’s hospitals were identified. Of those, 650 patients had a concerning feature on 
imaging, and 401 underwent serologic evaluation for tumor markers. Patients identified as 
having both concerning features on imaging and tumor marker testing comprised our cohort of 
401 patients. This cohort of high risk patients included 78 patients with a malignant neoplasm 
and 323 patients with benign pathologies (Table 3). Among the malignant neoplasms, the most 
common were germ cell tumors (n=39), sex cord stromal tumors (n=22), and epithelial ovarian 
tumors (n=12). There were no differences in age or race/ethnicity by malignancy status.  Imaging 
characteristics including the presence of free fluid, solid components, papillary projections, ill-
defined borders, extension, lymphadenopathy, and metastatic or complex components were 
significantly associated with malignant pathology (Table 3).  Further, malignant neoplasms were 
on average 15.1 cm, compared to 10.0 cm in benign neoplasms in this high-risk cohort 
(p<0.001).   
The rate of testing for tumor markers in this high-risk cohort varied considerably (Table 
4). The most frequently tested tumor markers were AFP at 94%, beta-hCG at 78%, CA 125 at 
54%, and LDH at 39%.  Less than 30% of patients underwent CA 19-9, Inhibin A, Inhibin B, 
and CEA testing. Patients with malignant pathologies were more likely to have any elevated 














Diagnostic accuracy of each tumor marker for any malignant pathology is presented in 
Table 5. The only tumor marker with high sensitivity was LDH.  Of the patients tested for LDH, 
98% of patients with malignant disease had elevated LDH. Sensitivity for all other tumors, or 
their ability to detect malignant disease was less than 60%. Several tumor markers had a 
specificity > 90% including CEA, AFP, Inhibin A, and Inhibin B. Of the patients tested for CEA, 
100% of patients with benign pathology had normal levels of CEA.  Similarly, of the patients 
tested for AFP, 98% of patients with benign disease had normal levels of AFP.   
CEA, AFP, and Inhibin A had the highest overall positive predictive value (PPV) for any 
malignancy (100%, 86%, and 82% respectively) (Table 5). All tumor markers tested had high 
negative predictive value (NPV), with the lowest being CEA at 78% (95% CI: 70%, 86%), and 
the highest being LDH at 92% (95% CI: 81%, 100%) (Table 5).  
 
Discussion  
This study demonstrates the variability in tumor marker testing during the workup of 
pediatric ovarian neoplasms. Although the role of tumor markers may vary based on suspected or 
confirmed pathology, our study shows that AFP, LDH, CA 125, CA 19-9, beta-hCG, CEA, 
Inhibin A, and Inhibin B may all be used to risk stratify pediatric patients with an ovarian 
neoplasm and help guide appropriate surgical management. However, while malignancy 
ultimately requires histopathological analysis, the high sensitivity, specificity, PPV, and NPV of 
the various tumors markers suggest that they are both valuable and accurate for preoperative risk 













Previous studies have evaluated different groupings of tumor markers, often concluding 
that any elevated tumor marker alone is a significant risk factor for malignancy. Papic et al. 
reported 150 pediatric patients undergoing ovarian surgery for a mass or cyst, of whom 110 had 
any tumor marker testing done (4). Notably, 40 of those 150 patients had a final diagnosis of a 
benign cyst (n=38) or endometriosis (n=2), which may have correlated with the reported rates of 
tumor marker testing. Of those patients who underwent testing, no patients with benign disease 
had an elevated AFP or beta-hCG. However, two patients with benign disease had elevated LDH 
and nine of thirteen patients with a malignancy (69%) had an elevated LDH. Overall, 83% of 
patients with a malignancy in this study had an elevated AFP, beta-hCG, or LDH.  Within our 
cohort, we also found that LDH has a high sensitivity but low specificity for malignancy.  
Oltmann et al. reviewed 424 pediatric patients who underwent ovarian surgery, of whom 
157 had tumor markers drawn, including beta-hCG, AFP, CA 125, and CEA. The exclusion of 
LDH as a tumor marker in this study may explain their low rate of any elevated tumor markers 
(54%) among patients with malignancy. An elevated beta-hCG, AFP, or CA 125 were 
significantly associated with malignancy on univariate analysis, but nearly the same number of 
patients with a malignancy (46%) did not have any elevated tumor markers. Notably, of the 46 
malignant cases they identified, only 35 of those patients had tumor markers drawn. It is unclear 
if this was due to urgent presentation of these patients or other clinical decisions. Tumor markers 
were elevated in 6.5% of patients with benign disease, indicating that one must also be aware of 
the possibility of false positives in tumor marker testing.  
One of the challenges in tumor marker testing is the variable origins of cell lines that may 
lead to ovarian malignancy in children, thus leading to different elevations in tumor markers 












sex cord stromal tumors, and epithelial tumors. In a retrospective review by Taskinen et al., 45 
patients who underwent surgery for an ovarian neoplasm at a single institution were evaluated. 
This report provided a descriptive look at tumor marker testing and results by pathology (1). 
Unfortunately, the small cohort made it difficult to identify any significant correlation, but the 
authors reported that AFP and CA 125 were most often associated with malignant pathology.  
Our study demonstrated trends in ovarian tumor marker analysis similar to those 
previously reported. The aforementioned articles each focused on different tumor markers as 
indicators for malignancy, highlighting the variability in the workup of pediatric patients with 
ovarian neoplasms. We also observed significant variation in the types and frequencies of tumor 
markers drawn (Table 4); our data demonstrate that any individual tumor marker may be 
necessary but not sufficient to preoperatively identify a pediatric ovarian malignancy.   
As ovarian malignancies in children arise from a variety of cell lines, broad laboratory 
testing becomes essential with preoperative concern for malignancy. Across our consortium, we 
recommend preoperative testing for potential ovarian neoplasms with AFP, beta-hCG, LDH, CA 
125, Inhibin A and Inhibin B. As the goal of this testing is to inform operative decision making 
by preoperative risk stratification, one of the challenges we observed is obtaining timely 
laboratory results. At some institutions, Inhibin A and B are outsourced, so results are often not 
available for several days. We advocate for consistent use of a standard preoperative panel of 
tumor markers if results are obtainable in a timely fashion.  
While not classically related to pediatric or adolescent ovarian pathology, CEA 
demonstrated 100% specificity and PPV in this study due to a single patient with malignant 
disease. However, its sensitivity was only 5% and NPV 78%, therefore adding CEA to a 












19-9, secreted by mucinous tumors of the gastrointestinal track and ovary, demonstrated low 
sensitivity and PPV, and only 73% specificity and 84% NPV; therefore, the addition of CA 19-9 
may not add significant value in the preoperative workup of pediatric patients with concern for 
an ovarian neoplasm. It has previously been demonstrated that preoperative CA 19-9 levels are 
not predictive that ovarian mucinous neoplasms will be benign, borderline, or malignant (12). 
Although we did not include estrogen or testosterone in our analysis, these tumor markers may 
be useful if a patient exhibits symptoms of hyperestrogenism or hyperandrogenism, such as may 
be seen with sex cord stromal tumors.  
Based on our results, we recommend utilizing a panel of tumor markers in patients with 
concerning ovarian lesions (AFP, beta-hCG, LDH, CA 125, Inhibin A, and Inhibin B) in order to 
minimize the risk of missing a malignancy. Unfortunately, we cannot determine the accuracy of 
using the panel of biomarkers in this cohort because all biomarkers were not obtained in all of 
our patients. Of the cohort of 401 patients, only 44 patients underwent the entire recommended 
panel of six tumor markers, and only eight underwent all eight markers analyzed. Due to the 
variability in testing of markers, we are limited in our ability to report on the diagnostic accuracy 
of the recommended panel of tumor markers as a whole. However, we are currently evaluating 
the accuracy of this panel of biomarkers for identifying malignancy in an ongoing prospective 
multi- institutional study. 
This study has several limitations. Our data were retrospective in nature and limited to 
patients with concerning features on imaging, so levels of testing were probably much higher in 
this cohort due to selection bias. It is unclear if diagnostic accuracy would be comparable in a 
cohort of all patients who present with any ovarian lesion regardless of imaging characteristics. 












borderline results may have variable interpretations. The challenge is that tumor markers are 
often only performed in patients with suspected malignancy, potentially changing estimates of 
sensitivity and specificity. With respect to sensitivity and specificity, prospective research 
evaluating tumor markers uniformly across all patients with pediatric ovarian neoplasms is 
needed.  However, tumor marker testing in the setting of simple cysts or other benign appearing 
ovarian lesions is not recommended.   
Conclusions 
Preoperative workup of pediatric patients with ovarian neoplasms remains challenging, 
particularly in situations in which imaging features may raise concern for malignancy. This study 
revealed that no single tumor marker provides an accurate enough prediction of malignancy to be 
used alone; rather, a panel of tumor markers may help guide surgeons in preoperative risk 
stratification and operative planning along with patient history, physical exam, and imaging 
findings. Prospective research further examining the accuracy of preoperative risk stratification 
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Table 1. Concerning features on imaging 
Size > 8 cm 























Table 2. Thresholds for abnormal laboratory testing 
CA 125 > 35 U/mL 
CA 19-9 >37 U/mL 
AFP > 10 ng/mL 
Quantitative beta-hCG > 2.3 mIU/mL 
LDH > 170 U/L 
CEA > 3 ng/mL 
Inhibin A > 80 pg/mL 
Inhibin B > 44 pg/mL for age 2-5 years; > 27 pg/mL for age 5-8; > 67 

























 N(%) or Median (IQR) N(%) or Median (IQR)  
Age  13.7 (10.5, 15.8) 13.5 (11.3, 16.4) 0.08 
Race/Ethnicity   0.20 
Non-Hispanic White 54 (69.2%) 194 (60.1%)  
Non-Hispanic Black 6 (7.7%) 55 (17.0%)  
Hispanic 6 (7.7%) 31 (9.6%)  
Other and Multiracial 7 (9.0%) 18 (5.6%)  




Septations 23 (29.5%) 109 (33.7%) 0.79 
Free Fluid 44 (56.4%) 124 (38.4%) 0.002 
Solid Components 62 (79.5%) 209 (64.7%) 0.003 
Papillary Projections 2 (2.6%) 1 (0.3%) 0.03 
Ill-Defined Borders 6 (7.7%) 9 (2.8%) 0.02 
Extension 6 (7.7%) 6 (1.9%) 0.005 
Lymphadenopathy 10 (12.8%) 9 (2.8%) <0.001 
Metastatic 18 (23.1%) 3 (0.9%) <0.001 
Complex 48 (61.5%) 147 (45.5%) 0.008 
Size of mass (cm) 15.1 (11.0, 22.0) 10.0 (6.2, 15.6) <0.001 
Elevated Tumor Markers    
AFP  31 (39.7%) 5 (1.5%) <0.0001 
LDH  42 (53.8%) 90 (27.9%) 0.02 
CEA  1 (1.3%) 0 (0.0%) 0.05 
CA 125  30 (38.5%) 31 (9.6%) <0.0001 
CA 19-9  2 (2.6%) 12 (3.7%) 0.89 
Beta-hCG  28 (35.9%) 60 (18.6%) 0.001 
Inhibin A  9 (11.5%) 2 (0.6%) <0.0001 
Inhibin B  10 (12.8%) 5 (1.5%) 0.0005 













Table 4: Proportion of Cohort that Received Tumor 
Marker Testing 
  Number tested Proportion Tested 
AFP  376 94% 
Beta-hCG 314 78% 
CA 125 218 54% 
LDH  157 39% 
CEA 103 26% 
Inhibin A 99 25% 
Inhibin B 92 23% 




















Table 5. Sensitivity, specificity, positive predictive value, and negative predictive values for 




















13% [6%, 19%] 32% [24%, 40%] 92% [81%, 100%] 
CEA  5% [0%, 13%] 
100% [100%, 
100%] 
100% [100%,100%] 78% [70%, 86%] 





49% [27%, 62%] 87% [81%, 92%] 
CA 19-9  25% [0%, 55%] 
73% [60%, 
86%] 




32% [22%, 42%] 85% [80%, 89%] 









92%[86%,99%] 67% [43%, 91%] 79% [70%, 88%] 
 
 
 
 
Journal Pre-proof
